1a). antibodies in patients with Chagas heart disease. Keywords: autoantibodies, 1-adrenergic receptor, chronic Chagas heart disease, immunoadsorption, [1,2]. Autoimmune responses against the 1-adrenergic receptor (1-AR) have been proposed to be involved in the pathogenesis of this cardiac disease [3C5]. Our findings show that antibodies directed against the ribosomal P2 protein of (TcP2) were able to cross-react with and stimulate the 1-AR. This reactivity was attributed to the highly antigenic acidic epitope present around the C-terminal end of the parasite ribosomal protein, named R13 (EEEDDDMGFGLFD), which bears similarity to an acidic motif (AESDE) on the second extracellular loop of the 1-AR [6C8]. Indeed, the functional effect of these autoreactive antibodies has been demonstrated using a classic pharmacological assay, considered the gold KRas G12C inhibitor 2 standard for assessment of anti-cardiac receptor antibody specificities, based on main culture of neonatal rat cardiomyocytes [7]. Because IgGs with strong anti-1-AR reactivity are associated with ventricular arrhythmias (VA) in cChHD [9,10], it has KRas G12C inhibitor 2 been suggested that their catecholamine-like action may play a major role in the pathophysiology of cChHD [3,6C8]. In experimental models, mice immunized with recombinant TcP2 protein that, in most cases, elicited anti-R13 antibodies with concomitant 1-adrenergic Rabbit polyclonal to AREB6 stimulating activity offered supraventricular tachycardia accompanied by premature death [8,11]. The pathogenic effect of this type of antibodies was confirmed by passive transfer of an anti-R13 monoclonal antibody (MoAb 172) [7] and its recombinant version, scFv C5 [12]. Both antibodies induced supraventricular tachycardia in recipient animals [7,12]. The presence of antibodies against 1-AR has also been explained in idiopathic dilated cardiomyopathy (IDC) [13,14]. Recently, Jahns immunoadsorption procedures suggests that this treatment might be used in the future to decrease the serum levels of anti-1-AR antibodies in patients with Chagas’ disease. Materials and methods Reagents Dulbecco’s altered Eagle’s medium (DMEM), DMEM:F12 (F-12), geneticin (G418 sulphate), penicillin G, streptomycin sulphate, LipofectamineTM reagent and pcDNA-31 eukaryotic expression vector transporting the NEO gene were obtained from Invitrogen Gibco (ny, USA). Bradford reagent was purchased from Bio-Rad (Hercules, CA, USA). NitrocelluloseHybond C membranes, I-[4,6-propyl-3H]dihydroalprenolol [(DHA), 359 TBq/mmol, 970 Ci/mmol] (C)-[3H]CGP-12177 (192 TBq/mmol, 520 Ci/mmol) and cAMP enzyme immunoassay (EIA) were purchased from Amersham Pharmacia (London, UK). Coraffin matrix was obtained from Fresenius Medical Care Affina GmbH (Berlin, Germany). Peroxidase conjugated anti-human IgG (H + l), atropine, DL-propranolol hydrochloride (C)-isoproterenol (+)-bitartrate salt (ISO) and bisoprolol were purchased from Sigma-Aldrich (St Louis, MO, USA). Texas red-labelled goat anti-mouse IgG (H + l) and goat anti-human IgG labelled with fluorescein isothiocyanate (FITC) were purchased from Jackson ImmunoResearch (Baltimore, USA). Patient population Serum samples were obtained from 32 patients with cChHD and 20 healthy individuals recruited in the beginning at the Ramos Mejia and Fernandez Hospitals, Buenos Aires, Argentina. The patients were then classified according to the severity of heart disease. Group I consisted of 20 patients with ventricular arrythmia (VA), group II comprised 10 patients with other rhythm disturbances and group III included two asymptomatic patients. Healthy individuals (HI) composed the control group. The study protocol complied with the Helsinki Declaration and was approved by the Committee for Ethical and Legal aspects of Research (CELAR) of the Instituto de Investigaciones en Ingenieria Genetica y Biologia Molecular, Buenos Aires, Argentina. Synthetic peptides Peptides R13 (representing C-terminal region of TcP2) and H26R (representing a region of the second extracellular loop of the human 1-AR) were synthesized as explained previously [7]. Monoclonal antibodies MoAb M16 raised against H26R peptide was prepared as explained in Mobini epimastigote lysate (50 g/well), recombinant glutathione S-transferase (GST)-TcP2 protein (2 g/ml) and both R13-bovine serum albumin (BSA) (1 M) or H26R (10 M) peptides were coated overnight at 4C in 005 M bicarbonateCcarbonate buffer (pH 96). Bound IgG fractions (dilution 1/50C1/200) were detected with peroxidase-conjugated anti-human IgG (H + l) at 37C for 1 h. Cut-off values were decided as explained in [10]. Sera with KRas G12C inhibitor 2 ratio values above the cut-off collection were.